IgA nephropathy: a paradigm shift in treatment strategies

View Full Paper

Ask AI

Bookmark

Authors

Discussion

This review explores new therapies and mechanisms in IgA nephropathy, suggesting a shift towards targeted treatments for kidney failure.

IgA nephropathy is the most common primary glomerular disease, greatly affecting kidney health worldwide.
Most diagnosed patients with IgA nephropathy are at risk of kidney failure without early, effective treatment.
Recent regulatory changes have spurred the development of targeted therapies specifically addressing IgA nephropathy mechanisms.
Four new therapies have been approved, offering the potential for early, well-tolerated interventions to reduce kidney failure risk.

Roberts et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark